Cell No. : Cell Name
RCB0882 : OCUB-F
update : 2021/02/26
|
| Comment | Same as OCUB-1, OCUB-M. |
| Comment from the depositor | Chromosome = pseudodiploid |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sawada, Tetsuji
|
| Originator |
Sawada, Tetsuji
|
| Year of deposit |
1993
|
| Original cell |
OCUB-1
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
53 years
|
| Tissue |
mammary gland, pleural fluid
|
| Disease name |
mammary tumor
|
| Metastastatic ability |
Yes
|
| Metastatsd tissue |
chest wall, pleura
|
| Classification |
cancer
|
| Year of origin |
1988
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS + 0.5mM Sodium Pyruvate
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 10 split
|
| SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| STR(human) |
|
OK
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
70-161(50) : /75(6),76(2),77(3),78(2),79(5),80(12)/
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
2
|
| User's Publication |
8
|
| Reference |
|
5477
Ikeda K, Yashiro M, Sawada T, Hato F, Hasuma T, Ishikawa T, Hirakawa-YSChung K.
M(R) 77 KDA factor derived from fibroblasts stimulates the invasion ability of breast-cancer cells.
Int J Cancer
2001
92(2):181-6
PubMed ID: 11291043
|
|
1881
Sawada T, Chung, Y S, Nakata B, Kubo T, Kondo Y, Sogabe T, Onoda N, Ogawa Y, Yamada N, Sowa M
[Establishment and characterization of a human breast cancer cell line, OCUB-1]
Hum Cell
1994
7:138-44
PubMed ID: 7873497
|
| User's Publication |
|
11747
Halilovic A, Verweij DI, Simons A, Stevens-Kroef MJPL, Vermeulen S, Elsink J, Tops BBJ, Otte-Höller I, van der Laak JAWM, van de Water C, Boelens OBA, Schlooz-Vries MS, Dijkstra JR, Nagtegaal ID, Tol J, van Cleef PHJ, Span PN, Bult P.
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
Sci Rep
2019
PubMed ID: 31406196
|
|
12199
Masashi Namba, Noboru Hattori, Hironobu Hamada, Kakuhiro Yamaguchi, Yohei Okamoto, Taku Nakashima, Takeshi Masuda, Shinjiro Sakamoto, Yasushi Horimasu, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Nobuoki Kohno
Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1
Cancer Lett
2019
442:31-39
PubMed ID: 30389434
|
|
8492
Hollestelle A, Elstrodt F, Timmermans M, Sieuwerts AM, Klijn JG, Foekens JA, den Bakker MA, Schutte M.
Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations.
Breast Cancer Res. Treat.
2010
122:125-33
|
|
8470
Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers H.
Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade.
J. Biol. Chem.
2009
284:35308-13
PubMed ID: 19850932
|
|
8695
Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E.
Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
Blood
2009
113:2715-22
PubMed ID: 19096014
|
|
5012
Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.
Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Hum Mol Genet
2006
15(6):821-30
PubMed ID: 16439445
|
|
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
|
|
13694
Kawamoto M, Shichijo S, Imai Y, Imaizumi T, Koga T, Yanaga H, Itoh K.
Expression of the SART-1 tumor rejection antigen in breast cancer
Int J Cancer
1999
80(1):64-7
PubMed ID: 9935232
|
Back
Top
CELL BANK Website
